Overview

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

Status:
Recruiting
Trial end date:
2024-10-28
Target enrollment:
Participant gender:
Summary
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC. Image acquisition is conducted using a PET/CT machine. * hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)
Phase:
Phase 1
Details
Lead Sponsor:
Nihon Medi-Physics Co., Ltd.